Niraparib – March 2023

• Brand names:
  • Zejula®
• Pharmaceutical Company:
  • GlaxoSmithKline Australia Pty Ltd
• Condition/Indication: Epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Meeting Date: March 2023
• Public Summary Document (PSD) March 2023 July 2023 PBAC Meetings - (PDF 1.1MB)
• Public Summary Document (PSD) March 2018 July 2023 PBAC Meetings - (Word 796KB)

Related Public Summary Documents

Niraparib – July 2023